ArticleJournal of hematology & oncology2018

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.

Stephen Couban et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.